ASX:HLSHealthcare
Is Healius (ASX:HLS) Using an Agilex Sale to Quietly Recast Its Core Pathology Focus?
In May 2026, Healius Limited (ASX:HLS) announced it had appointed UBS Securities Australia to explore a potential sale of its standalone Agilex Biolabs unit after receiving unsolicited approaches from several credible parties, while confirming any transaction would not affect its core Pathology operations.
This potential divestment highlights management’s ongoing efforts to reshape the portfolio toward pathology-focused activities and crystalise value from non-core clinical trials assets...